TheranosticTrials.org

Clinical Trial · NCT02766530

Integrated Positron Emission Tomography Magnetic Resonance (PET/MR) of Breast Cancer

Overview

The investigators will use integrated PET/MR for the goals below: 1. Use of PET-guided proton MRS (MR spectroscopy) and DCE MRI (dynamic contrast-enhanced MRI) for patients who will receive NAC (neoadjuvant chemotherapy) for breast cancer to monitor treatment response. 2. Use of dynamic and static PET to monitor treatment response for NAC, and to investigate the correlation of PET results versus MRS, DCE MRI. 3. Compare clinical staging by PET/MR and by clinical assessment. 4. On pre-chemotherapy studies, to investigate the association of molecular marker status with the dynamic and static PET, MRS and DCE MRI parameters.

Sponsor

National Taiwan University Hospital

Phase

Phase 4

Contacts

Ruoh-Fang Yen, MD, PhD (CONTACT)

rfyen@ntu.edu.tw

886223123456

Ruoh-Fang Yen, MD, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02766530

Drug / Compound

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Women with recently diagnosed breast cancer and who will receive NAC to reduce tumor burden before surgery. (including locally advanced breast cancer (LABC) according to clinical assessment; or tumor size \> 2cm, that is, at least T2 in TNM staging).

Exclusion

  • Women who received chemotherapy for other disease entity in recent 1 year.
  • Women who are pregnant or who are planning to be pregnant, or who are lactating (though the possibility in our target population should be very low)
  • Women who received metallic fixation, coronary artery stent in recent 3 months; or women who received mechanical valve replacement that is not compatible with MR magnet; or women with aneurysmal clips, pacemakers.
  • Estimated GFR (eGFR) \< 60 mL/min/1.73 m2 and blood glucose \> 135 mg/dl; Past or present history of acute renal failure, renal dialysis, diabetes mellitus.
  • Past history of breast cancer within recent 5 years before the currently diagnosed breast cancer.
  • Past history of claustrophobia.
  • Women who cannot cooperate with the examinations.